Lilly has been bringing in record revenue from its weight-loss medicines, but it has continued to diversify its pipeline candidates through acquisitions of biotech companies that are developing new ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果